Compare ZH & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZH | CVRX |
|---|---|---|
| Founded | 2011 | 2000 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 295.1M | 237.1M |
| IPO Year | 2021 | 2021 |
| Metric | ZH | CVRX |
|---|---|---|
| Price | $3.21 | $5.39 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $10.50 |
| AVG Volume (30 Days) | ★ 288.2K | 238.4K |
| Earning Date | 05-26-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $56,651,000.00 |
| Revenue This Year | N/A | $17.17 |
| Revenue Next Year | N/A | $17.69 |
| P/E Ratio | $20.74 | ★ N/A |
| Revenue Growth | N/A | ★ 10.45 |
| 52 Week Low | $2.57 | $4.37 |
| 52 Week High | $5.55 | $11.30 |
| Indicator | ZH | CVRX |
|---|---|---|
| Relative Strength Index (RSI) | 45.59 | 29.12 |
| Support Level | $3.09 | $5.11 |
| Resistance Level | $3.82 | $8.25 |
| Average True Range (ATR) | 0.14 | 0.60 |
| MACD | -0.03 | -0.16 |
| Stochastic Oscillator | 14.41 | 1.02 |
Zhihu Inc is engaged in the operation of one online content community which monetizes through paid membership services, marketing services and other services in the People's Republic of China. It is an online content community where people come to find solutions, make decisions, seek inspiration, and have fun. Its community supports discussions ranging from everyday consumer decisions, such as purchasing products or planning travel, to more specialized areas on professional knowledge, technological developments including artificial intelligence and academic topics. It operates in single segment and its revenues are derived from within the PRC.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.